Post by Regeneron
675,893 followers
The bottleneck was in the model. One-gene-at-a-time editing in traditional mice could not capture the complexity of the human immune system, which slowed discovery efforts. Using VelociGene®, our platform for large-scale DNA editing, we engineered mice with fully human immune systems. The work reflects principles set by our co-founder and CSO, George D. Yancopoulos, to focus on scalable, precise genetics that translate to patients. This approach helps remove key obstacles in antibody discovery and development. Watch to learn how we did it and why it matters for patients. https://bit.ly/4uuFoS8
Video Content